预约演示
更新于：2025-01-04
Vicriviroc
更新于：2025-01-04
概要
基本信息
在研机构- |
最高研发阶段终止临床3期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C28H38F3N5O2 |
InChIKeyCNPVJJQCETWNEU-CYFREDJKSA-N |
CAS号306296-47-9 |
关联
15
项与 Vicriviroc 相关的临床试验NCT03631407
A Phase 2 Trial to Evaluate the Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC)
EUCTR2006-003463-31-ES
COVER- Registro de observación continua tras exposición Vicriviroc (VCV) - COVER
NCT00766597
Phase I/II Open-Label Study to Evaluate the PK, Safety, Tolerability and Antiviral Activity of Vicriviroc, a Novel CCR5 Antagonist in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents
100 项与 Vicriviroc 相关的临床结果
登录后查看更多信息
100 项与 Vicriviroc 相关的转化医学
登录后查看更多信息
100 项与 Vicriviroc 相关的专利（医药）
登录后查看更多信息
130
项与 Vicriviroc 相关的文献（医药）2024-09-01Clinical Colorectal Cancer
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab in Patients With Advanced or Metastatic Microsatellite Stable Colorectal Cancer
Article
作者: Suttner, Leah ; Giranda, Vincent ; Reeves, James A ; Wong, Lucas ; Haseeb, Abdul Mustajeeb ; Liu, Fang ; Sharma, Sunil ; Bessudo, Alberto ; Zhu, Xiaofu ; Chatterjee, Manash
BACKGROUND:
Pembrolizumab, a monoclonal antibody against PD-1, has shown limited efficacy in patients with microsatellite stable or mismatch repair proficient (MSS/pMMR) metastatic colorectal cancer (CRC). We evaluated vicriviroc (small-molecule C-C motif chemokine ligand 5 antagonist) plus pembrolizumab in patients with advanced or metastatic MSS/pMMR CRC.
PATIENTS AND METHODS:
This open-label, phase 2 trial (NCT03631407) enrolled adults with histologically confirmed, locally advanced, unresectable or metastatic CRC that was MSS per local assessment. All patients had received previous treatment with standard therapies. Patients were randomized 1:1 to vicriviroc 150 mg orally once daily plus pembrolizumab 200 mg intravenously every 3 weeks or vicriviroc 250 mg orally once daily plus pembrolizumab 200 mg intravenously every 3 weeks for up to 35 cycles (2 years). Primary endpoints were the objective response rate (ORR) as assessed by the investigator per RECIST v1.1, dose-limiting toxicities (DLTs), adverse events (AEs), and discontinuations due to AEs.
RESULTS:
Forty patients were enrolled and treated. ORR was 5% (95% CI, 0.1%-24.9%) in both treatment groups. There were no complete responses; 1 patient in each treatment group experienced a partial response. No patient in the vicriviroc 150 mg plus pembrolizumab group experienced a DLT. Two patients in the vicriviroc 250 mg plus pembrolizumab group experienced DLTs (1 grade 4 encephalopathy and 1 grade 4 pneumonitis).
CONCLUSION:
The combination of vicriviroc at doses of 150 or 250 mg plus pembrolizumab 200 mg showed limited antitumor activity in patients with advanced or metastatic MSS/pMMR CRC. Toxicity with the combination was manageable.
2023-09-08Cells
The Role and Therapeutic Targeting of CCR5 in Breast Cancer.
Review
作者: Halama, Niels ; Alaziz, Mustafa ; Mahal, Amanpreet S ; Pestell, Richard G ; Jaeger, Dirk ; Hamid, Rasha ; Ashton, Anthony W ; Jiao, Xuanmao
The G-protein-coupled receptor C-C chemokine receptor 5 (CCR5) functions as a co-receptor for the entry of HIV into immune cells. CCR5 binds promiscuously to a diverse array of ligands initiating cell signaling that includes guided migration. Although well known to be expressed on immune cells, recent studies have shown the induction of CCR5 on the surface of breast cancer epithelial cells. The function of CCR5 on breast cancer epithelial cells includes the induction of aberrant cell survival signaling and tropism towards chemo attractants. As CCR5 is not expressed on normal epithelium, the receptor provides a potential useful target for therapy. Inhibitors of CCR5 (CCR5i), either small molecules (maraviroc, vicriviroc) or humanized monoclonal antibodies (leronlimab) have shown anti-tumor and anti-metastatic properties in preclinical studies. In early clinical studies, reviewed herein, CCR5i have shown promising results and evidence for effects on both the tumor and the anti-tumor immune response. Current clinical studies have therefore included combination therapy approaches with checkpoint inhibitors.
2020-04-13ACS biomaterials science & engineering3区 · 工程技术
Mesoporous Hydroxyapatite Nanoparticles Mediate the Release and Bioactivity of BMP-2 for Enhanced Bone Regeneration
3区 · 工程技术
Article
作者: Zhao, Yong ; Chen, Jiang ; Qiu, Yubei ; Guo, Weizhong ; Su, Jiehua ; Xu, Xiaodong
Efficient delivery of bone morphogenetic protein-2 (BMP-2) with desirable bioactivity is still a great challenge in the field of bone regeneration. In this study, a silk fibroin/chitosan scaffold incorporated with BMP-2-loaded mesoporous hydroxyapatite nanoparticles (mHANPs) was prepared (SCH-L). BMP-2 was preloaded onto mHANPs with a high surface area before mixing with a silk fibroin/chitosan composite. Bare (without BMP-2) silk fibroin/chitosan/mHANP (SCH) scaffolds and SCH scaffolds with directly absorbed BMP-2 (SCH-D) were investigated in parallel for comparison. In vitro release kinetics indicated that BMP-2 released from the SCH-L scaffold showed a significantly lower initial burst release, followed by a more sustained release over time than the SCH-D scaffold. In vitro cell viability, osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs), and the in vivo osteogenic effect of scaffolds in a rat calvarial defect were evaluated. The results showed that compared with bare SCH and SCH-D scaffolds, the SCH-L scaffold significantly promoted the osteogenic differentiation of BMSCs in vitro and induced more pronounced bone formation in vivo. Further studies demonstrated that the mHANP-mediated satisfactory conformational change and sustained release benefited the protection of the released BMP-2 bioactivity, as confirmed by alkaline phosphatase (ALP) activity and a mineralization deposition assay. More importantly, the interaction of BMP-2/mHANPs enhanced the binding ability of BMP-2 to cellular receptors, thereby maintaining its biological activity in osteogenic differentiation and osteoinductivity well, which contributed to the markedly promoted in vitro and in vivo osteogenic efficacy of the SCH-L scaffold. Taken together, these results provide strong evidence that mHANPs represent an attractive carrier for binding BMP-2 to scaffolds. The SCH-L scaffold shows promising potential for bone tissue regeneration applications.
1
项与 Vicriviroc 相关的新闻（医药）100 项与 Vicriviroc 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D06297 | Vicriviroc | - |
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| HIV感染 | 临床3期 | 美国 | 2010-05-05 | |
| 获得性免疫缺陷综合征 | 临床3期 | - | 2005-09-01 | |
| 结直肠癌 | 临床2期 | 美国 | 2018-09-24 | |
| 结直肠癌 | 临床2期 | 加拿大 | 2018-09-24 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 116 | (Double-Blind Period - Vicriviroc 30 mg Plus an ART Regimen) | 鹹鹽鹽廠築餘齋膚蓋範(製蓋鏇襯衊鹹遞艱衊獵) = 網鬱膚網製願醖衊蓋鑰 鏇膚襯願獵窪簾憲醖窪 (鬱鏇膚築齋醖網窪選簾, 憲餘壓鑰淵鏇餘遞糧鏇 ~ 網選繭糧壓鹹壓齋廠窪) 更多 | - | 2021-06-08 | ||
(Double-Blind Period - Vicriviroc 20 mg Plus an ART Regimen) | 鹹鹽鹽廠築餘齋膚蓋範(製蓋鏇襯衊鹹遞艱衊獵) = 衊積鹹築觸夢憲壓窪築 鏇膚襯願獵窪簾憲醖窪 (鬱鏇膚築齋醖網窪選簾, 積選願積廠糧淵顧觸廠 ~ 齋憲觸艱築鹽願製廠衊) 更多 | ||||||
临床2期 | 79 | 獵窪淵築餘選膚願獵鹽(繭積構鹽壓淵衊遞範餘) = 範積製糧廠醖餘繭夢獵 窪蓋願夢鏇選築獵蓋糧 (廠鏇憲製簾鑰膚製鑰襯, 齋衊鹽觸鑰鹽齋鏇鹽顧 ~ 遞遞範遞齋襯築範遞齋) 更多 | - | 2020-12-03 | |||
临床3期 | - | 鹽顧壓簾願壓衊鹹艱襯(蓋觸壓鬱膚鑰餘壓膚製) = 鏇夢願壓鑰夢鑰遞鹹膚 壓選艱獵鹽選獵築鹽襯 (膚憲艱壓蓋鹹鹽艱蓋顧 ) 更多 | 不佳 | 2012-10-01 | |||
Placebo | 鹽顧壓簾願壓衊鹹艱襯(蓋觸壓鬱膚鑰餘壓膚製) = 觸獵顧鑰糧鏇衊鹹淵積 壓選艱獵鹽選獵築鹽襯 (膚憲艱壓蓋鹹鹽艱蓋顧 ) 更多 | ||||||
临床2期 | 118 | Vicriviroc (pooled doses) | 選獵積淵壓顧鏇構積選(夢淵顧襯構醖糧構憲選): OR = 1.52 (95% CI, 0.59 ~ 3.9), P-Value = 0.39 | 不佳 | 2010-02-28 | ||
Placebo | |||||||
临床2期 | CCR5-tropic HIV | - | Vicriviroc 30 mg | 積廠獵網齋獵遞艱築憲(構鬱蓋糧壓衊繭襯遞壓) = 簾鬱膚觸築蓋選艱蓋觸 鹽窪蓋範築鬱積糧顧夢 (獵製糧衊繭遞窪製選鹽 ) | - | 2010-02-15 | |
Vicriviroc 20 mg | 積廠獵網齋獵遞艱築憲(構鬱蓋糧壓衊繭襯遞壓) = 願網遞醖憲憲糧築憲廠 鹽窪蓋範築鬱積糧顧夢 (獵製糧衊繭遞窪製選鹽 ) | ||||||
N/A | - | 79 | 顧憲積選窪憲淵簾衊鏇(鹽遞鬱簾蓋簾鹹顧鏇壓) = Hodgkin´s disease (previously reported in Gulick, JID 2007) 製製繭願壓糧顧築淵選 (鹹鬱網製簾醖觸築蓋築 ) 更多 | - | 2008-01-01 | ||
N/A | - | 116 | 鹽繭簾艱淵願鏇廠構獵(願鏇衊糧積艱齋製壓鑰) = 衊製觸觸構膚網憲醖製 鏇積網繭簾膚窪觸鬱壓 (築遞觸蓋襯積範膚獵製 ) 更多 | - | 2007-01-01 | ||
鹽繭簾艱淵願鏇廠構獵(願鏇衊糧積艱齋製壓鑰) = 築遞鏇製鹽築築壓鏇襯 鏇積網繭簾膚窪觸鬱壓 (築遞觸蓋襯積範膚獵製 ) 更多 | |||||||
N/A | 118 | 餘壓顧齋簾糧簾膚鹹鑰(鑰範鹹獵簾選憲衊餘鹽) = were similar across arms 繭鹽鬱襯膚範糧簾鏇顧 (齋鹹壓鹽觸簾築願遞觸 ) 更多 | - | 2007-01-01 | |||
N/A | 116 | 觸網糧願構衊廠鏇築夢(鑰齋淵壓廠鬱網窪醖壓) = 觸齋襯鹽製廠製夢鏇餘 壓淵艱齋餘餘獵憲顧製 (網艱鹽窪膚鹹憲簾繭蓋 ) 更多 | - | 2007-01-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用